Connect Biopharma Holdings (CNTB)

• Market cap: $159M
• 1 day: 1.44%
• 5 days: -6%
• 1 month: 1.08%
• 3 months: 33.02%
• 6 months: 51.61%
• Year to date: 11.9%
• 1 year: 341.45%
• 5 years: -83.46%
• 10 years: -84.75%
• Sector: Healthcare
• Industry: Biotechnology

About: Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Employees: 64